



MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE INTERNATIONAL CONFERENCE OF THE ALZHEIMER ASSOCIATION IN AMSTERDAM

Final recruitment stage of the Nanolithium study
in fall 2023, first results expected in Q1 2024

Montpellier, July 13, 2023 – 6 :00pm – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® nano-micelle oral delivery technology, announces its participation in the AAIC (Alzheimer’s Association International Conference).



Taking place in Amsterdam from July 16 to 20, 2023, the Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing the science of dementia.

Each year, AAIC brings together leading basic scientists, clinical researchers and clinicians to share the latest discoveries that will lead to development of prevention, treatment and improved diagnosis of Alzheimer’s disease.

Solène Guillot, Chief Medical Officer and Head of R&D at Medesis Pharma will be on site to meet key players in the field and present a scientific poster describing the design of the Phase II study, currently in progress, aimed at demonstrating the effect of NanoLithium® on behavioral and psychological symptoms in patients with mild to severe Alzheimer’s disease and explore the disease modifying potential.

Medesis Pharma’s NanoLithium study program has been prepared with Professor Jacques Touchon, former Dean of the Montpellier Faculty of Medicine and President of the last World Alzheimer’s Congresses in 2019, 2020 and 2021, who is also a member of the CTAD 2022 Scientific Committee and Medesis Pharma’s Permanent Scientific Advisory Board.

The study on 68 Alzheimer’s patients is ongoing in 8 university hospitals (CHU Montpellier, Toulouse, Paris, Lille, Lyon, Limoges, Marseille and Strasbourg). The first patients were included in Toulouse in June 2022, and the other CHUs began enrolling patients in November. Currently, more than half of the patients are included in the study, and full recruitment should be completed by end of fall 2023, with first clinical results expected in Q1 2024.

Medesis Pharma’s proprietary Aonys® technology is a blend of lipid components that spontaneously self-structure into a “water-in-oil” microemulsion. Aonys® enables the administration of low doses of water-soluble pharmaceutical active ingredients. The product is deposited on the mucous membrane of the mouth, then transported by lipoproteins and released directly into the cytoplasm of cells throughout the body using cellular lipoprotein receptors, crossing the Blood-Brain Barrier (BBB). Studies of native siRNAs encapsulated in Aonys® have demonstrated BBB passage, intracellular delivery, efficient targeted gene reduction and associated phenotypic results in mouse models.

For more information:

- [Download Medesis Pharma’s poster](#)
- [Visit AAIC conference website](#)



About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood–brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 12 patent families and 72 patents, resulting from 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FRO01844464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Jean Claude Maurel

Tel: +33 4 67 03 03 96

contact@medesispharma.com

CALYPTUS

Marie Calleux

Tel : +33 1 53 65 68 66

medesispharma@calyptus.net